Cero Therapeutics Files 8-K for Material Agreements

TL;DR

CERO filed an 8-K on Oct 14th for new deals and corporate changes.

AI Summary

Cero Therapeutics Holdings, Inc. filed an 8-K on October 16, 2025, reporting on events that occurred on October 14, 2025. The filing indicates an entry into a material definitive agreement, amendments to its articles of incorporation or bylaws, and other events. The company, formerly Phoenix Biotech Acquisition Corp., is based in South San Francisco, CA.

Why It Matters

This 8-K filing signals significant corporate actions by Cero Therapeutics, including new agreements and potential changes to its corporate structure, which could impact its future operations and stock.

Risk Assessment

Risk Level: medium — Material definitive agreements and amendments to corporate documents can introduce new risks or alter existing ones for the company and its investors.

Key Players & Entities

• CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
• October 14, 2025 (date) — Earliest event reported
• October 16, 2025 (date) — Filing date
• PHOENIX BIOTECH ACQUISITION CORP. (company) — Former company name
• SOUTH SAN FRANCISCO, CA (location) — Company business address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common stock, par value $0.0001 per share CERO Nasdaq Capital Marke
• $500,000 — n the Securities Purchase Agreement) by $500,000 to an aggregate of approximately $2.25
• $2.25 million — 00,000 to an aggregate of approximately $2.25 million of gross proceeds and reduce the size o
• $7 million — change to the aggregate amount of up to $7 million of proceeds to be funded pursuant to su
• $7 m — e Securities Purchase Agreement remains $7 million, of which $2.25 million was funde
• $4.75 million — n was funded at the Initial Closing and $4.75 million remains to be funded at the additional

Filing Documents

• ea0261237-8k_cero.htm (8-K) — 34KB
• ea026123701ex3-1_cero.htm (EX-3.1) — 294KB
• 0001213900-25-099560.txt ( ) — 614KB
• cero-20251014.xsd (EX-101.SCH) — 4KB
• cero-20251014_def.xml (EX-101.DEF) — 26KB
• cero-20251014_lab.xml (EX-101.LAB) — 36KB
• cero-20251014_pre.xml (EX-101.PRE) — 25KB
• ea0261237-8k_cero_htm.xml (XML) — 6KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On October 16, 2025, CERo Therapeutics Holdings, Inc. (the "Company") and the requisite Buyers (as defined in the Securities Purchase Agreement) party to the Securities Purchase Agreement (as defined below), entered into Amendment No. 1 to such Securities Purchase Agreement (the "SPA Amendment") to add an additional Buyer (as defined in the Securities Purchase Agreement) and increase the size of the Initial Closing (as defined in the Securities Purchase Agreement) by $500,000 to an aggregate of approximately $2.25 million of gross proceeds and reduce the size of the Additional Closings (as defined in the Securities Purchase Agreement) by an offsetting amount. There was no change to the aggregate amount of up to $7 million of proceeds to be funded pursuant to such Securities Purchase Agreement upon consummation of all of the Closings (as defined in the Securities Purchase Agreement) provided for therein.

03 Amendments to Articles of Incorporation

Item 5.03 Amendments to Articles of Incorporation of Bylaws; Change in Fiscal Year. On October 14, 2025, the Company filed the Certificate of Designations of Rights and Preferences of the Series E Preferred Stock (the "Certificate of Designations") for the purpose of designating and establishing the Company's Series E convertible preferred stock, par value $0.0001 per share (the "Series E Preferred Stock"). The Certificate of Designations was filed pursuant to the Securities Purchase Agreement, dated October 14, 2025, with certain accredited investors named therein (the "Securities Purchase Agreement"), as previously reported by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission on October 14, 2025 (the "Prior Form 8-K"). The Certificate of Designations became effective on October 14, 2025. The descriptions of the Series E Preferred Stock and the Certificate of Designations as previously reported in the Prior Form 8-K are incorporated by reference herein. Such descriptions do not purport to be complete and are qualified in their entirety by reference to the Certificate of Designations, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Other Events

Item 8.01. Other Events. On October 16, 2025, pursuant to the Securities Purchase Agreement, as amended, the Company and certain accredited investors named therein, mutually agreed to effect, and effected, the Initial Closing (as defined in the Securities Purchase Agreement), with respect to 3,816 shares of Series E Preferred Stock for gross proceeds of approximately $2.25 million. The aggregate amount to be funded pursuant to the Securities Purchase Agreement remains $7 million, of which $2.25 million was funded at the Initial Closing and $4.75 million remains to be funded at the additional closings. The rights, preferences and privileges of the Series E Preferred Stock are set forth in the Certificate of Designations. The offering and sale of the shares of Series E Preferred Stock were issued and, upon conversion of the Series E Preferred Stock, the shares of Common Stock underlying the Series E Preferred Stock will be issued, in each case, without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act") as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. The description of the terms and conditions of the Securities Purchase Agreement does not purport to be complete and each is qualified in its entirety by the full text of Securities Purchase Agreement filed as exhibit to the Prior Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 3.1 Certificate of Designation of Preferences, Rights and Limitations of the Series E Convertible Preferred Stock, dated October 14, 2025. 10.1* Securities Purchase Agreement, dated as of October 14, 2025, by and between CERo Therapeutics Holdings, Inc. and the investors signatory thereto (incorporated by reference to Exhibit 10.1 of the Company's Current Report on Form 8-K (File No. 001-40877) filed on October 14, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request. Certain portions of this document that constitute confidential information have been redacted pursuant to Item 601(b)(10) of Regulation S-K. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 16, 2025 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR